Viatris Inc.
Every calculator, already run for VTRS
Open the full toolkit →You have the numbers on VTRS. Get the argument.
A written report on which of these readings actually decide the outcome for Viatris Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering VTRSAnalyst Price Target Disagreement for Viatris Inc.
Wall Street's bull case implies +42% from the current price; the bear case implies -26%. A 68% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VTRS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as supp…
VTRS — frequently asked
Is VTRS a buy right now?
Wall Street's consensus rating on Viatris Inc. is Buy across 12 analysts, with a mean price target of $19.40 (+10% vs. the current $17.60). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is VTRS overvalued?
VTRS trades at — trailing earnings, against a DCF fair value of $73 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is VTRS's next earnings date?
Viatris Inc. is next scheduled to report earnings around Nov 5, 2026. A full VTRS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Viatris Inc.?
Analysts covering Viatris Inc. (VTRS) range from a bear-case target of $13.00 to a bull-case high of $25.00, with a mean consensus target of $19.40 across 10 analysts. The spread of $12.00 (68% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Viatris Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Viatris Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VTRS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Viatris Inc., in minutes. 3 free reports included with every account — no credit card required.